ATLANTA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary received an add-on status for the pricing and reimbursement approval for ILUVIEN in the Netherlands from the Ministry of Health, effective September 1, 2020. Pricing and reimbursement approval was sought and secured by Alimeras distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is in the process of reviewing launch plans.
We are extremely pleased to have received this national coverage decision for ILUVIENs diabetic macular edema and non-infectious posterior uveitis indications in the Netherlands at the same time, said Rick Eiswirth, President and Chief Executive Officer of Alimera. Given Horuss impressive performance on the launch of ILUVIEN in France, we look forward to expanding distribution and sales in the Benelux region, and continuing to execute on our international growth strategy.
ILUVIEN is a sustained release intravitreal implant indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapiesand for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU).
We are genuinely pleased that for the second time, our collaboration with Alimera Sciences regarding ILUVIEN in Europe, has been fruitful, said Maja Lausevic, Chief Operating Officer, Horus Pharma. Access to ILUVIEN therapy is widely anticipated by ophthalmologists and patients in the Netherlands, and we are enthusiastic to provide this unique therapeutic solution to them and look forward to the official launch.
About ILUVIEN
The Companys primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The 17 European countries include the U.K., Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czechia, the Netherlands, and Luxembourg. The non-infectious posterior uveitis indication for ILUVIEN was launched in Germany and the U.K. in 3Q 2019. ILUVIEN is not approved for treatment of uveitis in the United States.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.
About Non-Infectious Posterior Uveitis(NIPU)
Posterior segment non-infectious uveitis is a chronic, inflammatory disease affecting the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in developed and developing countries. It affects people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. Patients with NIPU are typically treated with systemic steroids, which are effective, but over time frequently lead to serious side effects, ranging from acne, weight gain, sleep and mood disorders to hypertension and osteoporosis that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which also can have severe side effects, including an increased risk of cancer and infection. As a result, there remains a significant need for new therapies with improved efficacy, tolerability, and safety profiles to manage this disease.
About Alimera Sciences, Inc.
http://www.alimerasciences.com
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit http://www.alimerasciences.com.
AboutHorus Pharma S.A.S.
Founded in 2003 in France, Horus Pharma is an independent European laboratory specialized in ophthalmology. It has been recognized to date as one of the main innovative European actors in corneal reconstruction treatments, particularly in the areas of dry eye, scarring and keratoconus. Focused on patient safety, Horus Pharma has developed recognized expertise in the development of preservative-free formulations and product delivery systems. For further details, please visit http://www.horus-pharma.com.
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimeras expectations with respect to access to ILUVIEN for patients in the Netherlands. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, Horus ability to launch ILUVIEN in the Netherlands for both uveitis and DME, the willingness of healthcare professionals and organizations in the Netherlands to adopt ILUVIEN for the two indications and Horuss ability to get pricing and reimbursement in the remaining Benelux countries, Belgium and Luxembourg, as well as other factors discussed in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Alimeras Annual Report on Form 10-K for the year endedDecember 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, which are on file with theSecurities and Exchange Commission(SEC) and available on theSECswebsite atwww.sec.gov.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Continue reading here:
Alimera Sciences Announces National Reimbursement Granted for ILUVIEN in the NetherlandsILUVIEN receives pricing and reimbursement approvals for both...
- Types of Blindness, Causes, and Their Treatment - Healthline - March 28th, 2025
- Types of blindness: Partial, total, congenital, and more - March 28th, 2025
- International collaborations helping understand the physical activity levels and well-being of children with visual impairment - Murdoch University - March 28th, 2025
- Revel in the Rainbow: Color-Blindness-Correcting Glasses Debut at Wooden Shoe Festival - Portland Monthly - March 28th, 2025
- Prevent Blindness Declares April as Women's Eye Health and Safety Month, Providing Free Educational Resources to the Public and Professionals - PR Web - March 28th, 2025
- Partial blindness hasn't stopped Oklahoma State's Stailee Heard from leading the Cowgirls into NCAAs - The Washington Post - March 28th, 2025
- Nine out of ten cases of blindness caused by glaucoma could be prevented through annual check-ups - Euro Weekly News - March 28th, 2025
- The silent sight thief: The devastating effects of glaucoma on mental health and quality of life - News24 - March 28th, 2025
- Rosie O'Donnell Celebrates Her 63rd Birthday After Move to Ireland as She Slams 'Willful Blindness' in Trump Administration - AOL - March 28th, 2025
- Partial blindness hasn't stopped Oklahoma State's Stailee Heard from leading the Cowgirls into NCAAs - Eagle-Tribune - March 28th, 2025
- The Longevity Wake-Up Call And The Blindness Of Leadership To It - Forbes - February 24th, 2025
- Album Review: Blindness // The Murder Capital - The Indiependent - February 24th, 2025
- The Murder Capital - Blindness - Northern Transmissions - February 24th, 2025
- The Murder Capital: Blindness review - independent pop | Indie - The Line of Best Fit - February 24th, 2025
- Prevent Blindness Kicks Off Second Annual "Retinopathy of Prematurity (ROP) Awareness Week," Feb. 24- March 2, 2025, as Part of its ROP... - February 24th, 2025
- Prevent Blindness Kicks Off Second Annual Retinopathy of Prematurity Awareness Week - Vision Monday - February 24th, 2025
- Gene therapy for rare childhood blindness shows lasting vision gains - R&D World - February 24th, 2025
- The Murder Capital's Blindness: A Voice of Significance in an Era Craving Authentic Discourse - Indie Is Not A Genre - February 24th, 2025
- Albums Of The Week: The Murder Capital | Blindness - Tinnitist - February 24th, 2025
- After Maine native testifies before Congress, Elon Musk targets his disability - Press Herald - February 24th, 2025
- Ozempic could BLIND you - it damages veins in the eye, major study finds - Daily Mail - February 24th, 2025
- Cerebral Venous Thrombosis Presenting With Binocular Blindness and Bilateral Sensorineural Hearing Loss - Cureus - February 24th, 2025
- Treatment for horses may lead to therapy for type of blindness - Mid Florida Newspapers - February 24th, 2025
- The Murder Capital: Blindness album review - Louder Than War - February 24th, 2025
- 'First in the world': London doctors cure blindness in children born with a genetic condition - WION - February 24th, 2025
- Doctors cure rare blindness in infants with gene therapy - NewsBytes - February 24th, 2025
- Gene therapy new trial treats rare blindness in children - Daily Jang - February 24th, 2025
- Ozempic Blindness Could Be Rare but Real: What Experts Say About the Risk - ZME Science - February 24th, 2025
- Parents of boy with rare eye condition hail amazing results of gene therapy - Yahoo News UK - February 24th, 2025
- Myths and Assumptions about Blindness - BBC.com - February 24th, 2025
- Man accused of beating victim, causing permanent blindness in one eye - KAIT - February 15th, 2025
- Scientists Find Link Between Weight Loss Drugs and Blindness - AOL - February 15th, 2025
- Treatment for horses may lead to therapy for type of blindness - University of Florida - February 15th, 2025
- How Ageism Impacts Adults with Low Vision - National Council on Aging - February 15th, 2025
- Ozempic and other weight loss drugs may be linked to conditions that could lead to blindness, study says - Quartz - February 15th, 2025
- Treatment for horses may lead to therapy for type of blindness - Phys.org - February 15th, 2025
- Treatment for Horses May Lead to Therapy for Type of Blindness - Morning Ag Clips - - February 15th, 2025
- Foundation Fighting Blindness Celebrates 20 Years of VisionWalk - PR Newswire - February 15th, 2025
- Woman Victim of 'Lash Blindness'Shock at How She Looks Without Them - Newsweek - February 15th, 2025
- Some Ozempic users are losing their vision - but scientists dont know why - The Independent - February 15th, 2025
- Those with visual impairments or blindness tackling the trails at Pico Mountain - WCAX - February 15th, 2025
- Prevent Blindness Issues Call for Nominations for the 2025 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award... - February 15th, 2025
- Medical warning: Ozempic and Mounjaro may be linked to vision loss - India Today - February 15th, 2025
- New research links Ozempic to vision loss and risk of blindness - MSN - February 15th, 2025
- Ozempic Blindness: Weight Loss Drugs Linked to This Condition, Experts Warn - Tech Times - February 15th, 2025
- Ozempic Blindness Lawsuit Mounts: Shocking Side Effect Of Weight Loss Drug Is 'Eye Stroke,' What You Need To Know - IBTimes UK - February 15th, 2025
- The Politics Of Erasure: Gaza, Genocide, And The Wests Wilful Blindness OpEd - Eurasia Review - February 15th, 2025
- WHO launches new initiative to tackle the main cause of vision impairment - December 19th, 2024
- Blindness Advocates on Why There Should Be Audio Description Oscars - Variety - December 19th, 2024
- Diabetic retinopathy is treatable and preventable but only if you catch it in time - USA TODAY - December 19th, 2024
- AI: Could it help prevent blindness in diabetics? - BBC.com - December 19th, 2024
- Health Officials Investigate Rare Form of Blindness Tied to Ozempic - Gizmodo - December 19th, 2024
- Ozempic Could Be Blinding People Trying to Lose Weight - VICE - December 19th, 2024
- What is retinitis pigmentosathe vision disorder in the movie Blink? - National Geographic - December 19th, 2024
- VR shows promise in aiding navigation of people with blindness or low vision - Health Tech World - December 19th, 2024
- Ozempic could be linked to a common cause of sudden blindness, study finds - Quartz - December 19th, 2024
- New virtual realitytested system shows promise in aiding navigation of people with blindness or low vision - Tech Xplore - December 19th, 2024
- Ex-meth user who gouged her own eyeballs out while high says she is happier years after nightmarish episode - New York Post - December 19th, 2024
- Officials investigating link between Ozempic and eye-rotting disease that makes people blind - Daily Mail - December 19th, 2024
- Youngster to 'have eye removed' after minor fall - but NHS waitlist 'over 3 years' - NationalWorld - December 19th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 19th, 2024
- COAVS and Fred Hollows Foundation strengthen efforts to combat blindness in Pakistan - 24newshd - December 19th, 2024
- Study finds link between Ozempic and increased risk of vision loss - The Express Tribune - December 19th, 2024
- Going blind at 33 is devastating I wont see my childrens faces as they grow up - The Telegraph - December 19th, 2024
- Europol terror report reveals stark blindness about where the danger lies - Gript - December 19th, 2024
- Elton John lost his vision; signs and symptoms of eye infections that can cause blindness - The Times of India - December 6th, 2024
- Elton John's battle with blindness: How 77-year-old star's husband David Furnish guided him around premiere as - Daily Mail - December 6th, 2024
- Experimental study shows connection between COVID infection and age-related blindness - Medical Xpress - December 6th, 2024
- Elton John confirms shocking blindness after severe infection fight: I havent been able to see.. - Hindustan Times - December 6th, 2024
- Yes, an Eye Infection *Can* Lead To Vision Loss Heres How - Katie Couric Media - December 6th, 2024
- Elton John Battling Partial Blindness After Serious Eye Infection - Digital Music News - December 6th, 2024
- CU Anschutz researchers working to cure blindness through total eye transplantation - 9News.com KUSA - December 6th, 2024
- Elton John lost his vision from an eye infection. Here's why that might happenand how to prevent it - Fortune - December 6th, 2024
- Elton John announces blindness due to infection - CBS19.tv KYTX - December 6th, 2024
- David Frost: I suffer from face blindness. As a politician, being unable to identify people is agony - The Telegraph - December 6th, 2024
- Hes still standing how Elton John has survived far worse than blindness - The Telegraph - December 6th, 2024
- Foundation Fighting Blindness Partners with University of Colorado Anschutz Medical Campus and Other Leading Institutions to Secure Up to $46 Million... - December 6th, 2024
- Walmart helping low vison and blind customers shop with new app - KSLA - December 6th, 2024
- Elton John Says He Is Blind In The Right Eye Due to An Infection; What Is It All About? - Times Now - December 6th, 2024
- Trumps Win: The Blindness of Republicans and Democrats - The Times of Israel - December 6th, 2024